nyasekai

Graveyard / Equity events

Biotech run-up before FDA decisions

Do small biotech stocks rise in the weeks before an FDA decision date?

Family
Equity events
Verdict
Dead
Cause
No edge
Buried
23 November 2026

The idea

Small biotech stocks often rally into an FDA decision date as traders position for good news. Buy about 30 trading days before the date and sell two days before the decision, so the binary outcome is never held.

How we tested it

DataCompany filings (8-K) that mention a PDUFA date, giving 899 events after an extension rule. Market cap between $100M and $2bn leaves 222 events; 71 were kept as primary trades. Long the stock from 30 trading days before the date to 2 days before, short the XBI biotech ETF.
Period2012 to 2026. Holdout 2021 to 2026; the earlier years are the development sample.
Costs60 bp for the stock and 5 bp for XBI, taken off every trade.
HoldoutDev and holdout were fixed in advance. Four variants (T-60, T-30, T-15, unhedged) were corrected for multiple testing, alpha 0.0167.
ControlA random twin: the same ticker with 5 random windows in the same year.

Result

Holdout events (primary)41
Holdout mean net of XBI−0.10% per event (t −0.03)
Holdout median / win rate−2.30% / 41%
Versus random twin, p value0.91
Dev sample (30 events)+3.71% (t 0.64, twin p 0.92)
Best twin p across variants0.45 (T-60, holdout)
Holdout, T-30 unhedged+2.41% (t 0.70, twin p 0.47)
Events with no usable priceabout 37%

Why it failed

The run-up is not there. The development result of +3.7% is noise, made of two halves with opposite signs (−3.5% and +10.9%). About 37% of events could not be priced, mostly delisted names that failed, so the sample leans toward survivors, which would flatter the strategy, and it still showed nothing. The test can only rule out an edge of about +3% per event or more.

What would make it worth retesting

Only with a price source that includes delisted companies and a clean FDA-action calendar.

Past results of a backtest say nothing certain about the future.